Advertisement
Letter to the Editor| Volume 57, ISSUE 1, P64-66, January 2010

Construction and immune response of HSV–2gD–Hsp70 DNA vaccine

  • Jianyong Fan
    Affiliations
    Department of Dermatology, Guangzhou General Hospital of Guangzhou Military Command (Liuhuaqiao Hospital), No. 111 Liuhua Road, Guangzhou 510010, People's Republic of China
    Search for articles by this author
  • Huilan Yang
    Correspondence
    Corresponding author. Tel.: +86 20 36653506.
    Affiliations
    Department of Dermatology, Guangzhou General Hospital of Guangzhou Military Command (Liuhuaqiao Hospital), No. 111 Liuhua Road, Guangzhou 510010, People's Republic of China
    Search for articles by this author
      Herpes simplex virus 2 (HSV-2) infections are common throughout the world. HSV-2 is the most common pathogen of genital herpes. As there are no curative therapies which can effectively control the recurrence of HSV infection, development of an effective and safe vaccine against HSV has become a hot point of research [
      • MasCasullo V.
      • Fam E.
      • Keller M.J.
      • Herold B.C.
      Role of mucosal immunity in preventing genital herpes infection.
      ]. It has been demonstrated that gD can induce significant cellular and humoral immune responses resulting in the protection of animals from lethal HSV infection [
      • Cooper D.
      • Pride M.W.
      • Guo M.
      • Cutler M.
      • Mester J.C.
      • Nasar F.
      • et al.
      Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses.
      ]. However, none was therapeutically effective and most were poorly immunogenic in human clinical trials [
      • Stanberry L.R.
      Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
      ]. The general failure of prior vaccines suggests the need to test other viral vaccine, particularly those capable of eliciting CD8+ T cell responses. A successful therapeutic vaccine may require different antigens and adjuvants than previously tried [
      • Stanberry L.R.
      Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
      ]. It has been well known that Hsps have adjuvant effect in peptide immunization to initiate specific cellular immune responses against associated antigens [
      • Sun J.C.
      • Bevan M.J.
      Defective CD8 T cell memory following acute infection without CD4 T cell help.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Dermatological Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • MasCasullo V.
        • Fam E.
        • Keller M.J.
        • Herold B.C.
        Role of mucosal immunity in preventing genital herpes infection.
        Viral Immunol. 2005; 18: 595-609
        • Cooper D.
        • Pride M.W.
        • Guo M.
        • Cutler M.
        • Mester J.C.
        • Nasar F.
        • et al.
        Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses.
        Vaccine. 2004; 23: 236-246
        • Stanberry L.R.
        Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
        Herpes. 2004; 11: 161A-169A
        • Sun J.C.
        • Bevan M.J.
        Defective CD8 T cell memory following acute infection without CD4 T cell help.
        Science. 2003; 300: 339-342
        • Gurunathan S.
        • Klinman D.M.
        • Seder R.A.
        DNA vaccines: immunology, application, and optimization.
        Annu Rev Immunol. 2000; 18: 927-974
        • Machiels J.P.
        • Van Baren N.
        • Marchand M.
        Peptide-based cancer vaccines.
        Semin Oncol. 2002; 9: 494-520
        • Fan J.Y.
        • Yang H.L.
        • Guan L.
        • Wang Y.
        • Shi Y.H.
        Prediction and clone of T cell epitope region of HSV-2 gD protein.
        Chin J Derm Venereol. 2007; 21: 330-333
        • Basu S.
        • Binder R.J.
        • Ramalingam T.
        • Srivastava P.K.
        CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin.
        Immunity. 2001; 14: 303-313
        • Binder R.J.
        • Blachere N.E.
        • Srivastava P.K.
        Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules.
        J Biol Chem. 2001; 276: 17163-17171
        • Sin J.I.
        • Kim J.J.
        • Arnold R.L.
        • Shroff K.E.
        • McCallus D.
        • Pachuk C.
        • et al.
        IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge.
        J Immunol. 1999; 162: 2912-2921